JP5706688B2 - Ｒａｇｅ融合タンパク質 - Google Patents

Ｒａｇｅ融合タンパク質 Download PDF

Info

Publication number
JP5706688B2
JP5706688B2 JP2010512391A JP2010512391A JP5706688B2 JP 5706688 B2 JP5706688 B2 JP 5706688B2 JP 2010512391 A JP2010512391 A JP 2010512391A JP 2010512391 A JP2010512391 A JP 2010512391A JP 5706688 B2 JP5706688 B2 JP 5706688B2
Authority
JP
Japan
Prior art keywords
rage
fusion protein
amino acid
acid sequence
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010512391A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529860A5 (https=
JP2010529860A (ja
Inventor
グレゴリー， ティー． ブレック，
グレゴリー， ティー． ブレック，
デーヴィッド， エム． ヒルバート，
デーヴィッド， エム． ヒルバート，
Original Assignee
ギャラクティカ ファーマシューティカルズ， インク．
ギャラクティカ ファーマシューティカルズ， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギャラクティカ ファーマシューティカルズ， インク．, ギャラクティカ ファーマシューティカルズ， インク． filed Critical ギャラクティカ ファーマシューティカルズ， インク．
Publication of JP2010529860A publication Critical patent/JP2010529860A/ja
Publication of JP2010529860A5 publication Critical patent/JP2010529860A5/ja
Application granted granted Critical
Publication of JP5706688B2 publication Critical patent/JP5706688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
JP2010512391A 2007-06-14 2008-06-13 Ｒａｇｅ融合タンパク質 Active JP5706688B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94399407P 2007-06-14 2007-06-14
US60/943,994 2007-06-14
PCT/US2008/066956 WO2008157378A2 (en) 2007-06-14 2008-06-13 Page fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015038891A Division JP5887441B2 (ja) 2007-06-14 2015-02-27 Ｒａｇｅ融合タンパク質

Publications (3)

Publication Number Publication Date
JP2010529860A JP2010529860A (ja) 2010-09-02
JP2010529860A5 JP2010529860A5 (https=) 2011-07-28
JP5706688B2 true JP5706688B2 (ja) 2015-04-22

Family

ID=40156919

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010512391A Active JP5706688B2 (ja) 2007-06-14 2008-06-13 Ｒａｇｅ融合タンパク質
JP2015038891A Active JP5887441B2 (ja) 2007-06-14 2015-02-27 Ｒａｇｅ融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015038891A Active JP5887441B2 (ja) 2007-06-14 2015-02-27 Ｒａｇｅ融合タンパク質

Country Status (17)

Country Link
US (3) US8398977B2 (https=)
EP (1) EP2158210B1 (https=)
JP (2) JP5706688B2 (https=)
KR (2) KR101595634B1 (https=)
CN (1) CN101842382A (https=)
AU (1) AU2008265983B2 (https=)
CA (1) CA2690056C (https=)
CO (1) CO6241158A2 (https=)
EC (1) ECSP099804A (https=)
ES (1) ES2564634T3 (https=)
IL (1) IL202443B (https=)
MX (1) MX2009013194A (https=)
NZ (1) NZ581550A (https=)
PL (1) PL2158210T3 (https=)
RU (1) RU2513695C2 (https=)
WO (1) WO2008157378A2 (https=)
ZA (1) ZA200908649B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20105110B (en) 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
PL2185589T3 (pl) 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
AU2010240569A1 (en) 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2011102845A1 (en) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
TWI542597B (zh) 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
ES2725852T3 (es) 2010-09-27 2019-09-27 Siwa Corp Eliminación selectiva de células modificadas por AGE para el tratamiento de la aterosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2013112986A1 (en) * 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
EP3711484A1 (en) * 2013-07-05 2020-09-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Soluble cd33 for treating myelodysplastic syndromes (mds)
EP3194439B1 (en) 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
JP6679096B2 (ja) * 2014-10-21 2020-04-15 学校法人 久留米大学 Ｒａｇｅアプタマーおよびその用途
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
KR20250053203A (ko) 2015-07-24 2025-04-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
CN110022898B (zh) 2016-12-09 2023-07-04 格利克尼克股份有限公司 用多价Fc化合物治疗炎性疾病的方法
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
JP6964322B2 (ja) * 2017-03-13 2021-11-10 学校法人 久留米大学 ループス腎炎を処置または予防するための医薬組成物およびループス腎炎のバイオマーカー
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
JP7307178B2 (ja) * 2018-09-14 2023-07-11 バイオエイジ ラブス， インコーポレイテッド 改善された安定性およびリガンド結合親和性を有するｒａｇｅ融合タンパク質ならびにその使用
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
CN118043351A (zh) * 2021-08-31 2024-05-14 上海医药集团股份有限公司 靶向Siglec15的抗原结合蛋白及其用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
DE69629176T2 (de) * 1995-01-18 2004-06-03 Alteon Inc. Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung
FI119756B (fi) * 1995-01-18 2009-03-13 Alteon Inc Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa
AU1832797A (en) 1996-01-26 1997-08-20 Trustees Of Columbia University In The City Of New York, The A polypeptide from lung extract which binds amyloid-beta peptide
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US5819341A (en) * 1996-05-24 1998-10-13 Simantob; Constance Collapsible and convertible combination baby bed and baby carrier system
US6790442B1 (en) * 1996-06-27 2004-09-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-γ
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
JP2001514661A (ja) 1997-03-11 2001-09-11 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病の処置における使用のための薬剤の同定
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6380165B1 (en) * 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6465422B1 (en) 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
WO2000018970A1 (fr) 1998-09-29 2000-04-06 Asahi Kasei Kabushiki Kaisha Procede de commande de liberation de granules
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
AU765719B2 (en) * 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6605642B2 (en) * 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6589944B1 (en) 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
CA2382095A1 (en) 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof
EP1219639A4 (en) 1999-09-08 2009-03-25 Toray Industries CIPO - Patent
CA2356207C (en) 1999-10-21 2012-10-09 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
JP2003516150A (ja) * 1999-12-08 2003-05-13 ジェンセット 潜在性分泌タンパク質をコードする全長ヒトｃＤＮＡ
NZ521437A (en) 2000-02-25 2004-04-30 Immunex Corp Integrin antagonists suitable as inhibitors of angiogenesis
US6716635B2 (en) * 2000-04-14 2004-04-06 University Of Kentucky Research Foundation Method for identifying regulators of protein-advanced glycation end product (protein-AGE) formation
AU2001255436A1 (en) 2000-04-17 2001-10-30 Transtech Pharma Protein expression system arrays and use in biological screening
US7140063B2 (en) 2000-05-05 2006-11-28 Osborne James J Multi-use and decorative bathing implement
JP2005520479A (ja) 2000-05-09 2005-07-14 ジェネティクス インスティテュート，エルエルシー 乾癬の確認、評価、予防および治療のための組成物、キットおよび方法
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US20020052475A1 (en) 2000-07-20 2002-05-02 Schering Ag High affinity soluble interleukin-18 receptor
DE60123998T2 (de) 2000-08-08 2007-09-06 Zymogenetics, Inc., Seattle Lösliche zcyctor 11 cytokinrezeptoren
US6825164B1 (en) * 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
CA2424246A1 (en) * 2000-10-02 2002-04-11 Shianlen Cahoon Methods and compositions for the treatment of inflammatory diseases
EP1373501A2 (en) 2000-10-06 2004-01-02 Novartis AG Targeting molecules for adenoviral vectors
AU2002213192A1 (en) 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
PL366250A1 (en) * 2000-12-29 2005-01-24 Reddy Us Therapeutics, Inc. Detection of compounds that modulate inflammatory responses
DE10164805B4 (de) 2001-02-28 2011-02-10 Koch-Pelster, Brigitte, Dr. Verfahren und Mittel zur Modifikation humaner Angiogenese
JP3837494B2 (ja) * 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
EP1575513A4 (en) * 2002-08-16 2007-04-04 Wyeth Corp COMPOSITIONS AND METHODS FOR TREATING RAGE-ASSOCIATED DISEASES
EP1771565B1 (en) * 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
SG161242A1 (en) * 2004-08-03 2010-05-27 Transtech Pharma Inc Rage fusion proteins and methods of use
GEP20105110B (en) * 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
WO2006036922A2 (en) * 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
EP1833976A2 (en) * 2004-12-03 2007-09-19 Xoma Technology Ltd. Methods and materials for expression of a recombinant protein
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
WO2007011606A2 (en) 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
SG171670A1 (en) 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
WO2008100470A2 (en) 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
WO2008137552A2 (en) 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
US20100254983A1 (en) 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases

Also Published As

Publication number Publication date
CN101842382A (zh) 2010-09-22
JP5887441B2 (ja) 2016-03-16
KR101361355B1 (ko) 2014-02-12
US9066927B2 (en) 2015-06-30
WO2008157378A3 (en) 2009-02-26
KR101595634B1 (ko) 2016-02-18
MX2009013194A (es) 2010-03-30
CA2690056C (en) 2017-08-29
NZ581550A (en) 2012-01-12
US20100291081A1 (en) 2010-11-18
IL202443B (en) 2018-05-31
US8398977B2 (en) 2013-03-19
CO6241158A2 (es) 2011-01-20
RU2010100913A (ru) 2011-07-20
EP2158210A2 (en) 2010-03-03
US9399668B2 (en) 2016-07-26
PL2158210T3 (pl) 2016-08-31
WO2008157378A2 (en) 2008-12-24
KR20130059461A (ko) 2013-06-05
RU2513695C2 (ru) 2014-04-20
EP2158210B1 (en) 2015-12-09
US20150368315A1 (en) 2015-12-24
IL202443A0 (en) 2011-08-01
ES2564634T3 (es) 2016-03-28
JP2015146809A (ja) 2015-08-20
JP2010529860A (ja) 2010-09-02
ECSP099804A (es) 2010-03-31
US20130177560A1 (en) 2013-07-11
EP2158210A4 (en) 2010-06-30
BRPI0813452A2 (pt) 2017-05-23
WO2008157378A8 (en) 2010-01-14
ZA200908649B (en) 2010-08-25
AU2008265983A1 (en) 2008-12-24
AU2008265983B2 (en) 2013-06-20
KR20100025574A (ko) 2010-03-09
CA2690056A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
JP5887441B2 (ja) Ｒａｇｅ融合タンパク質
AU765719B2 (en) Extracellular novel rage binding protein (EN-RAGE) and uses thereof
CN101137668B (zh) 与可溶性G蛋白偶联受体（sGPCR）有关的组合物与方法
DE69937573T2 (de) Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
JP2018508185A (ja) 骨格成長障害を治療するための可溶性ｆｇｆｒ３デコイ
KR20160002681A (ko) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
JPH07507684A (ja) Ｎｍｄａレセプター活性を有する新規ポリペプチド，これらのポリペプチドをコードする核酸，及び利用
Zhou et al. Studies of poly (ethylene glycol) modification of HM-3 polypeptides
DE60036199T2 (de) Proteaseresistente flint-analoge
UA78516C2 (en) Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
US20130039934A1 (en) Treatment of ige-mediated disease
US20170145105A1 (en) Vcam-1 mediated methods and compositions for treating aging-associated impairments
BRPI0813452B1 (pt) Proteína de fusão, seu uso, ácido nucléico e composição farmacêutica
DE10305082A1 (de) MIA-2 Protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110609

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20110609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130814

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130917

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140604

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150227

R150 Certificate of patent or registration of utility model

Ref document number: 5706688

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250